2019
Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles
Buza N, McGregor SM, Barroilhet L, Zheng X, Hui P. Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. Modern Pathology 2019, 32: 1180-1188. PMID: 30952972, DOI: 10.1038/s41379-019-0266-0.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, MissedAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChromosomes, Human, Pair 11CyclophosphamideDactinomycinEtoposideFemaleGenetic LociGenetic Predisposition to DiseaseHumansHydatidiform MoleMaleMethotrexatePhenotypePregnancyTreatment OutcomeTyrosine 3-MonooxygenaseUniparental DisomyUterine NeoplasmsVincristineConceptsPaternal uniparental isodisomyAbnormal trophoblastic proliferationCases of gestationUneventful clinical courseAggressive clinical behaviorUniparental isodisomyTyrosine hydroxylase locusMultiagent chemotherapyClinical courseFirst trimesterClinical complicationsImmunohistochemical featuresClinical behaviorMissed abortionAbnormal gestationsTyrosine hydroxylasePatientsTrophoblastic proliferationVillous cytotrophoblastsStromal cellsPhenotypical presentationChorionic villiGenetic conditionsP57 expressionGestation
2018
Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation
Wu X, Snir O, Rottmann D, Wong S, Buza N, Hui P. Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Modern Pathology 2018, 32: 650-658. PMID: 30443012, DOI: 10.1038/s41379-018-0179-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorColorectal Neoplasms, Hereditary NonpolyposisDNA-Binding ProteinsEndometrial NeoplasmsFemaleGenetic LociGenetic Predisposition to DiseaseHumansImmunohistochemistryMicrosatellite InstabilityMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinPhenotypePolymerase Chain ReactionPredictive Value of TestsReproducibility of ResultsConceptsEndometrial cancerMLH1/PMS2Endometrial carcinomaMSH6 lossMicrosatellite shiftCancer cohortMismatch repair deficiency testingMicrosatellite instability-high colorectal cancerEndometrial cancer cohortLoss of PMS2Clear cell carcinomaColorectal cancer cohortHigh colorectal cancerLynch syndrome familiesMSH2/MSH6PMS2 lossCell carcinomaColorectal cancerDeficiency testingSolid malignanciesColorectal carcinomaCarcinomaCancerIsolated lossMSH-6MicroRNA signatures discriminate between uterine and ovarian serous carcinomas
Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Human Pathology 2018, 76: 133-140. PMID: 29518404, DOI: 10.1016/j.humpath.2018.02.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCarcinomaDiagnosis, DifferentialFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansMicroRNAsMiddle AgedNeoplasm GradingNeoplasms, Cystic, Mucinous, and SerousOligonucleotide Array Sequence AnalysisOvarian NeoplasmsPhenotypePredictive Value of TestsReproducibility of ResultsRetrospective StudiesTranscriptomeUterine NeoplasmsConceptsHigh-grade serous carcinomaOvarian serous carcinomaSerous carcinomaOvarian malignancyPrimary ovarian high-grade serous carcinomaOvarian high-grade serous carcinomaMiRNA signatureEndometrial serous carcinomaHigh-grade ovarian serous carcinomaUterine serous carcinomaEndometrial counterpartOvarian primaryTaqMan Low Density Array technologySynchronous primariesEndometrial cancerMetastatic tumorsCarcinomaPrimary siteSignature panelPathological determinationMicroRNA signatureSignificant discriminatory powerCancer cellsMalignancyLineage characteristics
2015
Heterozygous bone marrow in a homozygous mature ovarian teratoma: a challenge to the germ cell theory or incidental somatic heterotopia?
Munday WR, Hui P. Heterozygous bone marrow in a homozygous mature ovarian teratoma: a challenge to the germ cell theory or incidental somatic heterotopia? Journal Of Clinical Pathology 2015, 68: 666. PMID: 25979987, DOI: 10.1136/jclinpath-2015-202959.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBiopsyBone MarrowCell LineageFemaleGenetic Predisposition to DiseaseGerm CellsHeterozygoteHomozygoteHumansOvarian NeoplasmsPhenotypeTeratoma
2013
Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal Of Clinical And Experimental Pathology 2013, 6: 1880-9. PMID: 24040454, PMCID: PMC3759496.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDNA Mutational AnalysisErbB ReceptorsExonsFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingHumansLung NeoplasmsMaleMiddle AgedMutationParaffin EmbeddingPhenotypePolymerase Chain ReactionPrecision MedicinePredictive Value of TestsPressurePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTissue FixationYoung AdultConceptsNon-small cell lung carcinomaCore needle biopsyCell lung carcinomaKRAS mutationsNSCLC patientsSurgical resectionEGFR mutationsLung carcinomaNeedle biopsyKRAS mutation analysisTyrosine kinase inhibitorsKRAS gene mutationsDirect sequencingMutation analysisFemale patientsAdenocarcinoma componentLung cancerPatientsEGFRExon 19Kinase inhibitorsExon 18Gene mutationsStatistical significanceResectionCancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability
Bossuyt V, Buza N, Ngo NT, Much MA, Asis MC, Schwartz PE, Hui P. Cancerous ‘floater’: a lesson learned about tissue identity testing, endometrial cancer and microsatellite instability. Modern Pathology 2013, 26: 1264-1269. PMID: 23558568, DOI: 10.1038/modpathol.2013.63.Peer-Reviewed Original ResearchConceptsEndometrial curettageBackground endometriumStaging surgeryEndometrial cancerEndometrial polypsEndometrioid adenocarcinomaEndometrial adenocarcinomaFurther workupPap smearSecretory endometriumDiagnostic workupEndometrial cellsDNA genotypingAdenocarcinoma tissuesMolecular testingMicrosatellite instabilityAllelic patternsAdenocarcinomaPatientsConfirmation of contaminationTissue fragmentsCurettageEndometriumWorkupMolecular pathologists
2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCase-Control StudiesFemaleGenes, rasGenetic MarkersGenetic Predisposition to DiseaseGenetic VariationHumansMiddle AgedOvarian NeoplasmsConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer
2005
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. The Journal Of Clinical Endocrinology & Metabolism 2005, 90: 6373-6379. PMID: 16174717, DOI: 10.1210/jc.2005-0987.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, PapillaryFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins B-rafThyroid NeoplasmsConceptsPapillary thyroid cancerBRAF mutation statusBRAF mutationsClinicopathological predictorsRisk stratificationClinicopathological outcomesThyroid cancerPTC subtypesMutation statusTumor stage III/IVStage I/II diseaseMultivariate analysisTumor BRAF mutation statusStage III/IVInitial tumor characteristicsLymph node metastasisPoor clinicopathological outcomesInitial surgeryRecurrent diseaseClinical courseIndependent predictorsNode metastasisClinicopathological characteristicsSubsequent recurrenceTreatment failure
2001
Bloom Syndrome in Sibs: First Reports of Hepatocellular Carcinoma and Wilms Tumor with Documented Anaplasia and Nephrogenic Rests
Jain D, Hui P, McNamara J, Schwartz D, German J, Reyes-Múgica M. Bloom Syndrome in Sibs: First Reports of Hepatocellular Carcinoma and Wilms Tumor with Documented Anaplasia and Nephrogenic Rests. Pediatric And Developmental Pathology 2001, 4: 585-589. PMID: 11826367, DOI: 10.1007/s10024001-0082-6.Peer-Reviewed Original Research